Clinical Research Of Hexue Prescription On Malignant Lymphoproliferative Disorders In Different Stages

Objective:This research aims to observe the clinical effect of Hexue on malignant lymphoproliferative disorders (MLPD) in different treatment stages.Methods:Forty MLPD cases were divided into two groups, control group (n=20) and treatment group (n=20). The control group only received chemotherapy, and the treatment group received chemotherapy combined with Traditional Chinese Medicine Hexue prescription. In treatment group, the patients received decoction of Tiaochangqiji and Hexuehuashi during chemotheray, and received decoction of Yiqiyangyin and Hexuejiedu during therapy interval. The follow-up time was twenty-four weeks. In both groups, we evaluated the performance status, quality of life, marrow toxicity, and CD4+/CD8+ratio.Results:1. Evaluating the performance status:the performance status had not significant differences between two groups before treatment; after treatment for twenty-four weeks, the performance status were higer than before treatment in treatment group(76±12.31vs85.26±8.42), while not in the treatment group, there is significant difference(P<0.05).2. Evaluating the life quality:the evaluation of life quality have not differences between two groups before treatment; after treatment, the quality of life (QoL) score was significantly higher after twenty-four weeks treatment than before in treatment group (40.2±5.55vs49.32±6.53)(P<0.05), while was decreased in control group(41.85±4.64vs39.16±7.69)(P>0.05), it is significantly different in total efficiency rate between two groups (47.3%vs5.3%)(P<0.01).3. Bone marrow toxicity:during chemotherapy, there were seven persons in treatment gruop, three persons’ grade of bone marrow toxicity was between zore and second(42.8%), three people were third(42.8%), one was fourth(14.2%); while in control group were six(46.1%),three (23.1%) and four(30.8%). there is not significantly different. In the zore to second grade, two groups were not different, and in the third grade, the percentage in treatment gruop is higher than control group, while is opposite in the fourth grade. The results suggest that Hexue prescription could reduce the degree of bone marrow suppression.4. T lymphocyte subpopulations:CD4+/CD8+ratio was compared before treatment and after treatment for twelve weeks, it was increased in treatment group(1.45±0.12vs1.541±0.17), while was decreased in control group(1.59±0.38vs1.48±0.37). There was significant difference between pre-and-post treatment (P<0.05). There was no significant difference between before treatment and other observe consequence in treatment group (P>0.05). The control group was showed a trend of decline. The results show that the traditional chinese prescription might improve the immunity in durable useage. Conclusion:The results suggested that chemotherapy combined with Hexue prescription in the patients of MLPD may improve the immunity, enhance the physical status, improve the quality of life, and reduce the degree of bone marrow suppression resulted foem the chemotherapy. It might be an approach to improve the clinical effect, slow disease progression in the future.